昊海生科(688366.SH):鹽酸莫西沙星滴眼液獲批上市
格隆匯3月10日丨昊海生科(688366.SH)公佈,近日,公司研製的鹽酸莫西沙星滴眼液用於治療細菌性結膜炎的上市註冊申請獲國家藥監局批准,公司為產品上市許可持有人,上海信誼金朱藥業有限公司作為產品受託生產企業。
該產品為公司自主研發的化學藥品,用於細菌性結膜炎的治療。截至本公吿日,國內市場中僅有由Novartis Pharmaceuticals Corporation註冊並由Alcon Laboratories, Inc.生產的鹽酸莫西沙星滴眼液於2018年底獲得國家藥監局批准註冊,公司預計將成為國內首個完成該產品仿製藥申請註冊的國產生產商。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.